Your personalized Breast Recurrence Score® report


What does your Breast Recurrence Score mean?

What a lower Recurrence Score means
The lower the Recurrence Score result, the lower the likelihood of your cancer coming back somewhere else in the body if you take endocrine therapy alone.
As your score increases, the magnitude of chemotherapy benefit also increases.

What a higher Recurrence Score means
The higher the Recurrence Score result, the higher the likelihood of your cancer coming back somewhere else in the body if you take endocrine therapy alone.
As your score increases, the magnitude of chemotherapy benefit also increases.


How likely is it that your breast cancer will return?
A distant recurrence risk of 8% means out of 100 patients, 8 will have their breast cancer return at another site in their body within 10 years.


Will chemotherapy help?


Getting a second—and third—opinion
“I want people to know that cancer doesn’t always mean a death sentence. We have come so far, and you can take this type of experience and make it better.”


What does your Breast Recurrence Score mean?

What a lower Recurrence Score means
The lower the Recurrence Score result, the lower the likelihood of your cancer coming back somewhere else in the body if you take endocrine therapy alone.
As your score increases, the magnitude of chemotherapy benefit also increases.

What a higher Recurrence Score means
The higher the Recurrence Score result, the higher the likelihood of your cancer coming back somewhere else in the body if you take endocrine therapy alone.
As your score increases, the magnitude of chemotherapy benefit also increases.


How likely is your breast cancer to return?

5-year risk of distant recurrence2
- Premenopausal patients with a Recurrence Score result of 0-100
1,2,6 - Postmenopausal patients with a Recurrence Score result of 0-25
1,2,6

5-year risk of distant recurrence or mortality2
- Postmenopausal patients with a Recurrence Score result of 26-100
1,2

Will chemotherapy help?

The decision to forgo chemotherapy
Nina feels fortunate that her cancer was caught early, and that she was able to benefit from a genomic test that put her on a much simpler medical path.
Have questions?
References
- Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
- Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829-1834.
- Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
- Sparano JA, Crager M, Gray RJ, et al. Clinical and genomic risk for late breast cancer recurrence and survival. NEJM Evid. 2024;3(8):EVIDoa2300267.
- Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336-2347.
Oncotype DX, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, and Recurrence Score are registered trademarks of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. All other trademarks are the properties of their respective owners.
The Oncotype DX Breast Recurrence Score test was developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The Oncotype DX Breast Recurrence Score test is performed at the Genomic Health Redwood City clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority.